IFNG and systemic lupus erythematosus: Fisetin has been reported to inhibit IFN-γ-stimulated inflammation [35] and ameliorate IFN-γ-related diseases, including systemic lupus erythematosus [36], sclerosis [37], and rheumatoid arthritis [38], in in vivo models.